Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 326
- Registration Number
- NCT01119859
A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas
Phase 2
Completed
- Conditions
- Brainstem Glioma
- Interventions
- Radiation: Radiation therapy
- First Posted Date
- 2010-05-06
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT01118377
A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT01116830
A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)
Phase 4
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT01117129
A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
Phase 2
Completed
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01115491
A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01107418
An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia
Completed
- Conditions
- Anemia
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6000
- Registration Number
- NCT01105494
A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT01099904
A Study of Balapiravir in Patients With Dengue Virus Infection
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT01096576
A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Phase 3
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcgDrug: Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 131
- Registration Number
- NCT01095835
© Copyright 2025. All Rights Reserved by MedPath